ArticleCancers2023
Update on Calcitonin Screening for Medullary Thyroid Carcinoma and the Results of a Retrospective Analysis of 12,984 Patients with Thyroid Nodules.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Flushing: Neuroendocrine Mechanisms and a Structured Diagnostic Approach.Clinical endocrinology · 2026Review
- Combined Detection of Preoperative Serum Calcitonin and Carcinoembryonic Antigen in Medullary Thyroid Carcinoma: A Retrospective Multicenter Cohort Study.Health care science · 2026Article
- [Successful selpercatinib treatment of metastatic medullary thyroid cancer carrying rare RET variant].Magyar onkologia · 2026Article
- Persistent Hyperprocalcitoninemia as the Initial Diagnostic Clue to Sporadic Medullary Thyroid Carcinoma.European journal of case reports in internal medicine · 2026Article
- Circulating Biomarkers in Medullary Thyroid Carcinoma: Bridging Laboratory Complexities and Clinical Application Through Algorithm Design.Journal of clinical medicine · 2025Review
- A Comparative Study on the Multidimensional Features of Hereditary and Sporadic Medullary Thyroid Carcinoma Patients: A Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- Calcitonin as Biomarker for the Medullary Thyroid Carcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- Epidemiology, Clinical Presentation, and Diagnosis of Medullary Thyroid Carcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- Diagnostic advances in medullary thyroid carcinoma.Endocrine oncology (Bristol, England) · 2025Article
- Article
- Diagnostic Performance of Preoperative Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Medullary Thyroid Carcinoma in Patients with Graves' Disease-A Case Series and Literature Review.Journal of clinical medicine · 2024Article
- Diagnostic, Theranostic and Prognostic Value of Thyroglobulin in Thyroid Cancer.Journal of clinical medicine · 2024Review
- Management of Thyroid Nodules.Sisli Etfal Hastanesi tip bulteni · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe provide an update on calcitonin (Ctn) screening for the early detection of medullary thyroid carcinoma (MTC) and present the results of a large single-center analysis evaluating sex-specific cut-off-levels and long-term courses.
methodsA total of 12,984 consecutive adult patients (20.1% male and 79.9% female) with thyroid nodules who had undergone routine Ctn measurement were retrospectively analyzed. Patients with confirmed suspicious Ctn values were referred for surgery.
resultsCtn measurements were elevated in 207 (1.6%) patients, with values below twice the sex-specific reference limit in 82% of these cases. Further clarification was possible in 124/207 cases, of which MTC could be ruled out in 108 cases. Histopathological assessment confirmed MTC in 16/12,984 patients.
conclusionsOur extrapolated MTC prevalence of 0.14% is significantly lower than that described in early international screening studies. The stimulation test can usually be dispensable when using a decision-making concept based on sex-specific basal Ctn cut-off values. Ctn screening is recommended even in patients with very small thyroid nodules. High quality standards in pre-analytics, laboratory measurements, and the interpretation of data must be ensured, as well as close interdisciplinary cooperation between medical disciplines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.